sumatriptan/naproxen

{{Short description|Pharmaceutical product}}

{{Use dmy dates|date=June 2022}}

{{Infobox drug

| type = combo

| image =

| width =

| alt =

| caption =

| component1 = Sumatriptan

| class1 = Triptan

| component2 = Naproxen

| class2 = Nonsteroidal anti-inflammatory drug (NSAID)

| tradename = Treximet, Suvexx, others

| Drugs.com = {{drugs.com|monograph|sumatriptan}}

| MedlinePlus =

| licence_EU =

| DailyMedID = Sumatriptan naproxen

| licence_US =

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category =

| routes_of_administration = By mouth

| ATC_prefix = N02

| ATC_suffix = CC51

| ATC_supplemental =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA = Rx-only

| legal_CA_comment = {{cite web | title=Regulatory Decision Summary - Suvexx | website=Health Canada | date=23 October 2014 | url=https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?lang=en&linkID=RDS00698 | access-date=7 June 2022}}

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US = Rx-only

| legal_US_comment = {{cite web | title=Treximet- sumatriptan succinate and naproxen sodium tablet, film coated | website=DailyMed | date=14 April 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42ddf376-8dc0-4236-be2a-0c6ae92ece04 | access-date=7 June 2022}}

| legal_EU =

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status =

| CAS_number =

| CAS_supplemental =

| PubChem =

| IUPHAR_ligand =

| DrugBank =

| ChemSpiderID =

| UNII =

| KEGG = D11577

| ChEBI =

| ChEMBL =

| synonyms =

}}

Sumatriptan/naproxen, sold under the brand name Treximet among others, is a fixed-dose combination medication used to treat migraines. It is taken by mouth. It contains sumatriptan, as the succinate, a serotonin 5-hydroxytryptamine (5-HT) 1b/1d receptor agonist (triptan); and naproxen as the sodium salt, a member of the arylacetic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs).

Medical uses

Sumatriptan/naproxen is indicated for the acute treatment of migraine with or without aura in people twelve years of age and older.

A Cochrane review in 2020 found that the combination of sumatriptan plus naproxen was better than placebo for relieving acute migraine attacks in adults. When the starting headache intensity was mild, 5 in 10 (50%) of people treated with the combination were pain-free at two hours compared with about 2 in 10 (18%) with placebo. Almost 6 in 10 (58%) people with moderate or severe pain who were treated with the combination had pain reduced to mild or none at two hours, compared with 3 in 10 (27%) with placebo. The combination was also better than the same dose of either drug given alone in these people. Results were 5 in 10 (52%) people with sumatriptan alone or about 4 in 10 (44%) with naproxen alone.{{cite journal | vauthors = Law S, Derry S, Moore RA | title = Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults | journal = The Cochrane Database of Systematic Reviews | volume = 4 | issue = 4 | pages = CD008541 | date = April 2016 | pmid = 27096438 | doi = 10.1002/14651858.CD008541.pub3 | pmc = 6485397 }}

Side effects

Some of the listed side effects include dizziness, nausea, sleepiness, dry mouth, pain in neck, throat or jaw, numbness or tingling.{{cite web | url = https://www.drugs.com/treximet.html | title = Treximet | work = Drugs.com }}

References

{{Reflist}}